glp 1 drugs and breast cancer GLP-1 Receptor Agonist Use Weight Change in Patients With GLP-1 weight loss drugs are

doi:10.1016/S1262-3636(08)73398-6 Secher A, Jelsing J, Baquero AF, Hecksher-Srensen J, Cowley MA, Dalbge LS, Hansen G, Grove KL, Pyke C, Raun K, Schffer L, Tang-Christensen M, Verma S, Witgen BM, Vrang N, Bjerre Knudsen L

For patients on broader longevity or optimization protocols, GHK-Cu injections may also be combined with NAD+ therapy, BPC-157, or other peptides depending on their clinical goals

Its important to note that weight loss with Ozempic is gradual, and results may continue to improve over time

Researchers tracking retatrutide versus semaglutide data and retatrutide dosing protocols will find that this triple agonist could eventually overtake both CagriSema and tirzepatide